• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Data sharing measures improving

Report: Data sharing measures improving

September 10, 2014
CenterWatch Staff

Citeline, an Informa business unit, has reported that clinical trial transparency, also known as responsible data sharing, is in a much healthier state than shown in previous studies.

"Prior analyses found that 23% to 57% of completed clinical trials do not report results. However, these analyses only included trials that met specific criteria and none included conference abstracts as a source for results disclosure. As such, I wanted to know what the current status is for results reporting among industry sponsors using broader inclusion criteria and across multiple sources for results," said Doro Shin, a Citeline analyst.

For her analysis, Shin used Citeline's Trialtrove, a competitive intelligence resource that draws data from over 30,000 sources. The analysis focused on nearly 7,500 phase II-III industry-sponsored trials with primary completion dates between 2008 and 2012 to determine how many of these trials provided results in peer-reviewed sources (defined as a journal manuscript or conference abstract) or at clinicaltrials.gov.

Of all of the phase II-III studies reviewed, a surprising 78% provided final or interim results across all sources. When looking just at the phase III trials, the most expensive and high-profile trials for sponsors, 81% provided final or interim results.

Shin's findings also focused on the disclosure rates among the top 20 pharma companies, which range from 55% to 98% when all sources are consulted. Amgen appears to be the most dedicated to reporting, with 98% of its phase III trials in the dataset showing results, followed closely by AstraZeneca and Celgene. Most sponsors report phase III results in both peer-reviewed sources and at clinicaltrials.gov. However, some companies such as Astellas and Roche seem to favor posting their results only in peer-reviewed sources.

"Although sponsor companies are in fact assuming some degree of risk by reporting clinical trial results, either positive or negative," said Shin, "it is refreshing to see that they are becoming more and more committed to industry initiatives to improve transparency."

From a competitive intelligence perspective, this improved access to trial results data leads to better informed strategic decisions and increased R&D productivity, provided the right sources are consulted. From an overall societal perspective, it helps provide better information to patients participating in trials and to those who eventually will benefit from new or improved medicines.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing